From genomics pioneer to prevention leader: why Greater Manchester could shape the future of diagnostics and prevention-led care
Greater Manchester has long been a centre for scientific discovery. What is changing now is its ability to turn that innovation into practical benefits for patients, and to do it at scale.
The Government’s recent announcement designating Greater Manchester as a Prevention Demonstrator creates an opportunity to ensure proven innovations reach patients faster and more consistently, improving patient outcomes, reducing pressure on the NHS and saving the system money.
At the heart of the region’s success to date is a uniquely integrated ecosystem. World-class universities, one of the UK’s largest NHS trusts, and a dense network of home-grown life sciences companies sit side by side along the Oxford Road Corridor. This proximity enables collaboration to move beyond strategy into day-to-day practice, supported by access to a 3 million-strong integrated care record that allows real-world evidence to be generated alongside clinical use.
Collaboration between entrepreneurial, forward thinking and solutions focused clinical academics at the University of Manchester helped foster the evolution of genedrive, a company now focused on rapid pharmacogenetic testing. Today, these technologies are enabling time-critical treatment decisions in stroke and neonatal care, helping to prevent avoidable harm before it occurs.
As the NHS shifts from treatment to prevention, the regions that lead will be those that can integrate preventive diagnostics into routine care, not just as pilots, but as standard of care. Greater Manchester’s devolved leadership, together with organisations such as Health Innovation Manchester, has the potential to create the conditions to align policy, clinical practice, and industry to support adoption at scale.
The challenge now is to ensure that this progress is sustained and replicated. Without clear and consistent pathways for implementation, even the most effective innovations risk being slowed by fragmentation and local variation.
Greater Manchester is moving beyond being a genomics pioneer, with the potential to show what a prevention-led, precision medicine system could look like at scale.
By Dr Gino Miele, CEO of genedrive plc
